Context and Objective: Soluble Klotho (sKlotho) is a circulating hormone with cardiovascular-renal protective effects. Whether sKlotho predicts estimated glomerular filtration rate (eGFR) decline in patients with type 2 diabetes mellitus (T2DM) with relatively preserved renal function is unknown.
K
lotho is an antiaging gene encoding a transmembrane protein that works as an obligate coreceptor for fibroblast growth factor-23 (FGF-23) to promote phosphorus excretion (1, 2) . The cleavage of the extracellular portion of the transmembrane protein produces a circulating hormone, named soluble Klotho (sKlotho), which per se may induce phosphaturia independently of FGF-23 and exert cardio-renal benefits through reduction in oxidative stress and endothelial protection (3) . The kidney is the main source of circulating sKlotho (4) . In cross-sectional studies, sKlotho levels decline with advancing stages of chronic kidney disease (CKD) (5, 6) . More recent prospective studies suggest that reduced levels of sKlotho predict a decline in renal function and cardiovascular mortality in elderly nondiabetic subjects and in patients on hemodialysis, respectively (7) . Animal data support the concept that Klotho may be not just a biomarker but also a pathogenic factor in CKD progression and cardiovascular complications (8) . In vivo replacement of sKlotho attenuates renal damage in animal models of kidney disease (9) . We have recently described an association between reduced levels of sKlotho and microalbuminuria (MA) in patients with type 1 diabetes (10) .
To date, there are no long-term prospective studies that have evaluated if sKlotho levels predict renal function decline in patients with type 2 diabetes mellitus (T2DM). We therefore studied if sKlotho levels predicted renal function decline in 101 patients with T2DM, all with estimated glomerular filtration rate (eGFR) .45 mL/min at baseline, who were followed for a median of 9 years (range, 2 to 13 years).
Material and Methods
Patients were recruited from the Diabetes Clinic at Guy's and St Thomas' Hospitals (London, UK) from 2004 to 2006. All patients provided written informed consent. The study was approved by the institutional research ethics committee and undertaken in adherence to the Declaration of Helsinki.
Inclusion criteria were patients older than 40 years of age with T2DM as per the World Health Organization definition, diagnosis and classification of diabetes mellitus criteria (11) , and evidence of diabetic kidney disease (history of MA and no evidence of nondiabetic kidney disease). History of MA was defined as early morning urine albumin to creatinine ratio .3 mg/mmol on at least two occasions. Exclusion criteria were clinical or biochemical evidence of substantial renal impairment (eGFR ,45 mL/min) or history of nondiabetic kidney disease.
There were no patients on vitamin D or phosphate binders. Patients were followed up with standardized clinical and biochemical measurements as per routine clinical care with annual or biannual visits.
Plasma-sKlotho (Immuno-Biological-Laboratories, Hamburg, Germany) and plasma C-terminal FGF-23 (Immunotopics Inc., San Clemente, CA) were measured in duplicate by enzyme-linked immunoassay from samples stored at 280°C (10, 12, 13) . The intra-assay and interassay coefficients of variation for sKlotho and FGF-23 enzyme-linked immunoassay were 2.7% and 6.5% and 4.4% and 6.1%, respectively. Blood samples were immediately centrifuged at 1500g at 4°C for 10 minutes, and the supernatant fractions were stored at 280°C with no freezethaw cycles before analysis. This approach has been shown not to affect the sensitivity of the assay used in this study (12) . Serum phosphate was measured in duplicate by spectrophotometry (Pointe Scientific Inc., Canton, MI) (10). Urine albumin concentration was measured by immunoturbidimetry using a Cobas Miras Plus analyzer (Roche Diagnostics, Rotkreuz, Switzerland) from three timed overnight urine collections, and the median albumin excretion rate (AER) was calculated. Serum total cholesterol (enzymatic colorimetry) and creatinine levels were measured using a Cobas Mira Plus analyzer (Roche Diagnostics) (14) . Hemoglobin A1c (HbA1c) was measured by boronate affinity high-performance liquid chromatography (CLC330; Primus, Kansas City, MO). eGFR was determined using the Chronic Kidney Disease Epidemiology Collaboration Formula (15) .
Statistical analysis
Descriptive statistics were used for the analysis of demographic and clinical features of the cohort. AER and sKlotho levels were log transformed before calculation because of their positively skewed distribution. Between-group differences were compared by unpaired t test (for continuous parametrically distributed variables) and Mann-Whitney test (for continuous nonparametrically distributed variables). A x 2 test was used to compare categorical variables between groups. The primary outcome was defined as the time to event of .50% fall in eGFR from baseline. Because death precludes us from observing declines in kidney function, we considered death from any cause to be a competing event in our cohort and fitted a cause-specific Cox proportional hazards model (16) and a subdistribution hazards model to adjust for death as a competing risk event (17) (18) (19) . By following the subdistribution hazards approach, we are able to relate the covariate effect directly to and calculate the cumulative incidence function for each of the events (17) (18) (19) . The cumulative incidence function allows for estimation of the incidence of the occurrence of an event while taking competing risks into account. For each patient, a linear regression model of time on eGFR (least-squares method) was created, and the slope of the regression line was used to estimate the patient's changes of eGFR over time (20) . Statistical analyses were performed using SPSS software (version 24; SPSS Inc., Chicago, IL) and R (version 3.4.2) statistical programming language with cmprsk package (version 2.2-7) for the subdistribution hazards analysis.
Results
Baseline clinical and demographic characteristics of the cohort are shown in Table 1 . The mean age was 60 years (range, 40 to 82 years), ;60% were male, the mean duration of diabetes (mean 6 SD) was 9.8 6 6.6 years, and mean eGFR was 90.7 6 20.0 mL/min. Median Of the 101 patients, 92 (91%) were on renin angiotensin system (RAS) inhibitors (Table 2) . Of this group, 39 (38.6%) patients were normoalbuminuric (AER ,20 mg/min), and 53 (52.5%) had raised AER (.20 mg/min) despite RAS inhibitor use. There were no significant differences in age, duration of diabetes, FGF-23, serum phosphorus, serum calcium, eGFR, and HbA1c between patients with normoalbuminuria on RAS treatment as compared with those with raised AER (Table 2) . However, patients with raised AER had significantly higher SBP levels, a raised body mass index, more frequent use of statins, a greater number of oral hyperglycemic agents, and lower sKlotho levels as compared with those with normoalbuminuria ( Table 2 ). The significant difference in sKlotho levels between the two groups persisted after adjustment for SBP, body mass index, eGFR, statin treatment, and the use of oral hypoglycemic agents [odds ratio, 0.02; 95% confidence interval (CI), 0.001 to 0.36; P = 0.007] ( Table 3 ). In further analyses we evaluated the relationship between sKlotho and eGFR and AER. sKlotho levels were significantly, albeit modestly, inversely correlated in univariate analyses with baseline AER (Spearman correlation coefficient, 20.245; P = 0.01). In contrast, no significant correlation between sKlotho and baseline eGFR was observed.
In our cohort, patients in the lowest quartile of sKlotho levels had a faster rate of decline in eGFR as compared with those in the highest quartile (median, 23.3 mL/min/y; IQR, 21.73 to 24.48 mL/min/y vs median, 21.43 mL/min/y; IQR, 0.01 to 22.8 mL/min/y; P = 0.01).
Of the 101 patients, 21% (n = 22) reached the primary outcome of a .50% decline in eGFR from baseline, and 17.8% (n = 18) died before reaching a .50% fall in eGFR. Table 4 shows the characteristics of patients above and below the median baseline sKlotho value of 204.4 pg/mL. As compared with patients above the median sKlotho level, a higher degree of albuminuria and lower HbA1c were observed in patients below the median. There were no significant differences in age, sex, SBP, FGF-23, cholesterol, use of RAS blockers, and diabetes duration between patients above and below the median value of sKlotho. Figure 1 shows the estimates for the cumulative incidence function curves for the primary outcome for patients with baseline sKlotho below the median value for the cohort of 204.4 pg/mL vs those above the median. The cumulative incidence for those below the median approached 24%, and for those above the median baseline sKlotho levels reached 6.2% after 10 years of follow up.
The end-of-study mean eGFR for the whole cohort was 68.5 6 28.5 mL/min. In patients who had a fall in eGFR of .50% from baseline, the mean end-of-study eGFR was 30.3 6 13.0 mL/min, as compared with 79.1 6 21.7 mL/min in those without a .50% fall in eGFR (P = 0.001).
We fitted cause-specific and subdistribution hazards models for both renal function decline and death before decline in kidney function. For each of the two events, we regressed hazards on baseline covariates (age, sex, eGFR, SBP, HbA1c, albuminuria, and total cholesterol and sKlotho levels). Estimated hazard ratios and their associated 95% CIs are reported in Table 5 . Baseline sKlotho did not predict risk of death before reaching the primary outcome of renal function decline in both the causespecific and subdistribution hazards models. A oneunit increase in the log-transformed sKlotho decreased the relative incidence of the event by 72% (hazard ratio, 0.28; 95% CI, 0.15 to 0.52; P , 0.001) when adjusted for multiple risk factors (Table 5 ). This indicates that a 10% increase in the baseline levels of sKlotho results in a 12% decrease in the relative incidence of the primary outcome.
Discussion
In this prospective study, we report that sKlotho is an independent predictor of .50% decline in eGFR in patients with T2DM with relatively preserved renal function. This effect of sKlotho was independent of FGF-23, calcium and phosphate levels, and traditional renal risk factors. We also observed that patients with residual albuminuria despite RAS blockade had significantly lower levels of sKlotho as compared with patients with normoalbuminuria on RAS, a finding that has not been described previously. Moreover, patients in the lowest quartile of sKlotho had a 1.8 mL/min/y faster annual rate of eGFR decline than patients with the highest levels of sKlotho. We also observed that patients with sKlotho level below the median for the group had a nearly four times higher incidence of loss of .50% of their renal function during a 10-year follow-up. Numerous cross-sectional studies, in predominantly nondiabetic cohorts, have reported an inverse association between sKlotho levels and eGFR. In a study with 87 patients (six with diabetes) with CKD stages 1 to 5, sKlotho levels were inversely associated with eGFR (5).
More recently, in a prospective study of 2496 elderly subjects (37% with diabetes) with a mean baseline eGFR of 73 mL/min, doubling of sKlotho levels was independently associated with reduced risk of fall in renal function (defined as a .30% reduction in eGFR from baseline) (7) .
In a study by Lee et al. (21) , patients with T2DM and preserved renal function (mean eGFR, .90 mL/min) had significantly lower levels of sKlotho compared with nondiabetic control subjects. The authors reported that sKlotho levels were inversely related to the degree of albuminuria; however, none of the patients studied was on RAS inhibition. Of this cohort, 109 patients were followed for a median 34 months, and the authors observed a negative correlation between sKlotho levels and decline in eGFR (22) .
In another cross-sectional study of patients with T2DM with CKD stages 1 to 4, an inverse relationship between sKlotho levels and degree of albuminuria was observed (23) . However, the concurrent use of RAS inhibitors was not reported. In the same cohort, no correlation was found between sKlotho and FGF-23 or other measures of mineral or bone metabolism (24) .
In a recent study, we observed that patients with type 1 diabetes with MA (all on RAS inhibitors) had lower levels of sKlotho as compared with normoalbuminuric patients of similar duration of diabetes who were not on any other antihypertensive medications (10) . Further, the significant difference in sKlotho levels we observed between the two groups was independent of levels of vitamin D and parathyroid hormone.
There are limited prospective studies that have evaluated the role of sKlotho in patients with CKD. In a post hoc analysis of a prospective study of 243 patients with CKD stage 1 to 5 (30% with eGFR ,30) predominantly due to glomerulonephritis (64%) and with only 12% with diabetic kidney disease, lower levels sKlotho independently predicted the composite outcome (doubling of serum creatinine, onset of renal end stage disease, or death) after adjustment for age, diabetes, blood pressure, eGFR, parathyroid hormone, and FGF-23 (25) . Only 69% of patients in this cohort were on RAS blockade. In a more recent study in 769 patients on hemodialysis (31% with diabetes) followed for 2 years, patients with raised sKlotho levels had a 14% reduced occurrence of cardiovascular events and cardiovascular death compared with those with lower levels (26) .
The potential mechanism by which sKlotho exerts cardiorenal protective effects remains unclear. In rodents, Klotho deficiency is associated with kidney fibrosis and vascular calcification (6, 9, 26) . Conversely, sKlotho replacement reverses or attenuates the kidney damage, ameliorates endothelial dysfunction, and prevents the development of vascular calcification (9) . In animal studies, overexpression of the Klotho gene reduces oxidative stress, renal cell hypertrophy, inflammation, and apoptosis (27, 28) . Activation of the RAS has been proposed as the main pathological mechanism leading to reduction in Klotho expression through increased oxidative stress (27, 28) . We have previously demonstrated that RAS blockade increases the levels of sKlotho in patients with T2DM (14) .
Our study has several limitations. The cohort of patients we studied was relatively small because we excluded subjects with more severe renal impairment, Figure 1 . Estimates of the effect of sKlotho on the cumulative incidence curves of risk for primary outcome of .50% eGFR decline from baseline in 101 patients with T2DM with relatively preserved renal function at baseline. which is known to affect sKlotho levels. Larger studies are required to confirm our findings, and our results establish the rationale for such future studies. We could not measure vitamin D or parathyroid hormone levels because we did not have sufficient volumes in our stored samples for these analyses. However, sKlotho can exert its effects independent of these variables, and changes in Klotho occur prior to clinically relevant alterations in these markers (29) (30) (31) . The baseline blood pressure of the cohort was not optimal and reflects the limitations of using patients referred to a hospital clinical service. Despite similar blood pressure control, patients with residual albuminuria on RAS had significantly lower levels of sKlotho as compared with those without albuminuria. The mechanisms by which sKlotho protects against progression of renal function decline are unclear. Our study was not designed to evaluate putative mechanisms by which sKlotho provides renoprotection. However, we can speculate based on data from animal studies that sKlotho, a multifaceted protein, may have direct renoprotective effects modulated via multiple pathways that may be independent of its traditional role in phosphate balance, such as actions on endothelial dysfunction and oxidative stress and enhancing anti-inflammatory pathways, which are relevant to driving the progression of diabetic renal disease (28, (32) (33) (34) (35) . The strengths of our study are that all the patients had relatively preserved renal function (eGFR .45 mL/min) and were a well-characterized cohort attending a single center for their diabetes care over a long follow-up period. Our primary outcome of a .50% decline in eGFR is a robust and validated definition of clinically important renal function decline (36, 37) . The final mean eGFR of those with progression of renal disease was ;30 mL/min, this indicates that it is very unlikely that the observed fall in renal function was due to resolution of hyperfiltration.
Our results suggest that a 10% higher sKlotho level reduces the incidence of the primary outcome by 12%; this effect is independent of traditional risk factors. We performed competing risk analyses using recommended methods (38, 39) , which demonstrated a consistent and substantial independent effect of sKlotho on the primary renal outcome. More than 90% of our patients were on RAS blockade, and the effects we observed were independent of other markers and predictors of renal disease progression. We did not observe any impact of FGF-23 or serum phosphate levels on progression of renal disease. This would suggest that changes in sKlotho may precede alterations in FGF-23 and phosphate and that sKlotho is the likely primary driver of progression of renal dysfunction. This hypothesis is supported by animal studies that demonstrate that sKlotho may induce phosphaturia by FGF-23-independent mechanisms (30, 40).
However, because sKlotho has a reno-protective effect via multiple biological pathways, the effects we observed may be independent of its role in phosphate balance (3, 8) .
In summary, we have demonstrated that, in a clinic cohort of patients with T2DM with relatively preserved renal function, lower levels of sKlotho are associated with residual albuminuria and faster progression of renal function decline. Our results complement the animal and in vitro data that indicate sKlotho may be a potential treatment target to delay progression of renal dysfunction and support the emerging role of sKlotho as a potential biomarker and predictor of renal disease in diabetes.
